COMMUNIQUÉS West-GlobeNewswire

Glow Holdings, Inc. Provides Corporate Update Following GlohCo Introduction and Initial Industry Engagement
04/02/2026
HOUSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Glow Holdings, Inc. (OTC: GLOH), doing business as GlohCo, today provided a corporate update following the recent introduction of its GlohCo health intelligence platform and [...]
MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
04/02/2026
Agreement expands offering to include additional sheet, particulate and flowable products MARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it [...]
HealthEdge Awarded ‘Best in KLAS’ Designation for Pre-Payment Integrity
04/02/2026
HealthEdge Source™ Ranks Highest Overall in Pre-Payment Accuracy & Integrity Market and is the Only Solution to Increase its Score Year Over Year, According to Customer Assessments BOSTON, Feb. 04, 2026 (GLOBE [...]
Novo Nordisk files annual report with the SEC
04/02/2026
Bagsværd, Denmark, 4 February 2026 – Novo Nordisk A/S has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of [...]
PerfectServe is Again Best in KLAS for Physician Scheduling and Ambulatory Clinical Communications
04/02/2026
Awards reinforce company’s decades-long mission to deliver measurable outcomes in scheduling and care coordination for healthcare organizations MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- PerfectServe ® , a leading [...]
INVO Fertility Issues Shareholder Letter Highlighting Strengthened Fundamental Position and Strategic Outlook for Growth
04/02/2026
SARASOTA, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ la société pharmaceutique de [...]
Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer
04/02/2026
DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation from FDA Clinical entry validates condensate modulator discovery platform and its potential to [...]
Communiqué établissant le bilan semestriel du contrat de liquidité de la société CROSSJECT
04/02/2026
Communiqué de Presse Communiqué établissant le bilan semestriel du contrat de liquidité de la société CROSSJECT Dijon, le 04 février 2026 Au titre du contrat de liquidité confié par la société CROSSJECT à Rothschild [...]
H1 Named to the 2026 DHNY Hall of Fame After Five Years of Recognition
04/02/2026
Honoring the companies that helped build the foundation of New York's digital health ecosystem NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- H1 , on a mission to connect the world with the right doctors, today announced [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
04/02/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 04 février 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) la société pharmaceutique de [...]
SAFE - Croissance de 6,5 % du chiffre d’affaires 2025 - Confirmation de la feuille de route
04/02/2026
Croissance de 6,5 % du chiffre d’affaires 2025 Confirmation de la feuille de route Fleurieux-sur-l’Arbresle - France - le 4 février 2026 à 18h. Safe Group publie son chiffre d’affaires annuel consolidé pour l'exercice [...]
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
04/02/2026
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment [...]
Branded Legacy, Inc. (OTC: BLEG) Successfully Negotiates Retirement of Four Additional Convertible Notes, Preventing Potential Dilution of Hundreds of Millions of Shares
04/02/2026
Company has decisively eliminated $1,078,500 in legacy convertible debt VANCOUVER, British Columbia, Feb. 04, 2026 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG ), today announced that Interim Chief [...]
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the [...]
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
04/02/2026
T he Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, [...]
New Study Finds Use of Psychiatric Collaborative Care Model Has Expanded Rapidly for Children and Adults, but With Enormous Disparities Among States
04/02/2026
Key organizations call on 14 state Medicaid agencies to reimburse for CoCM to improve patient outcomes and reduce total healthcare costs for Medicaid, Medicare and commercial plans WASHINGTON, Feb. 04, 2026 (GLOBE [...]
TruFull CBD Gummies | Launch "CBD Gummies Safe Relieves Anxiety Effective Reduces Pain & Stress With TruFull CBD 2026
04/02/2026
Discover TruFull CBD Gummies 2026 – A trusted, hemp-based CBD supplement created to help manage stress, and support physical comfort safely. New York City, Feb. 04, 2026 (GLOBE NEWSWIRE) -- In today’s fast-paced [...]
Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™
04/02/2026
Two-year follow-up data demonstrate sustained benefit, including improvements in pain, fatigue and bone health, following single low dose of avigbagene parvec (FLT201) Robust improvements in lyso-Gb1, a surrogate [...]

Pages